Medical progress isn't just about new therapies; it's also about de-escalation, such as reducing the number of radiotherapy sessions. This type of innovation significantly improves a patient's quality of life by minimizing the exhaustive and disruptive time spent in treatment, a benefit patients value highly.

Depression is highly prevalent in the advanced endometrial cancer population, affecting up to 50% of patients. It is often missed by clinicians and unreported by patients, despite its significant impact on treatment adherence and mortality.

As various maintenance therapies (immunotherapy, ADCs) are integrated into endometrial cancer treatment, the next major clinical question is defining how long these agents need to be continued to maximize benefit while minimizing long-term toxicity and patient burden.

While immunotherapy is transformational for DMMR endometrial cancer, its benefit is much smaller for the PMMR majority (two-thirds of patients). This reality requires more nuanced patient counseling and selective use in this population.

In late-stage metastatic colorectal cancer, the goal shifts from achieving significant tumor shrinkage to stabilizing the disease. This recalibration of 'success' focuses on maintaining quality of life and managing symptoms for patients who have undergone multiple prior therapies.

The most significant, lasting effects of treatment toxicities on quality of life often become most apparent *after* therapy has concluded. Clinical trials that stop collecting data shortly after treatment completion miss this crucial long-term impact, underestimating the true burden of side effects.

Palliative care, or supportive oncology, is engaged at the very beginning of a patient's journey with metastatic pancreatic cancer. This early integration helps manage the high symptom burden from the disease and treatment toxicities, improving quality of life from day one, rather than being a tool reserved for end-of-life care.

Mirroring success in rectal cancer, a new trial is exploring neoadjuvant immunotherapy for localized, MSI-high endometrial cancer. This strategy could potentially allow patients to avoid surgery and radiation, which is a particularly compelling option for those who wish to preserve their fertility.

Patients are often unprepared that finishing active treatment or achieving "no evidence of disease" is not the end of their struggle. Survivorship introduces a distinct phase of challenges, including managing long-term side effects, PTSD, and fear of recurrence, which requires different support.